Evaluation of etravirine resistance in clinical samples by a simple phenotypic Test

Journal of Medical Virology

Volumn 85, Issue 4, 2013, Pages 703-708

  Agneskog, Eva ^a   Nowak, Piotr ^a   Källander, Clas F R ^b   Sönnerborg, Anders ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Cavidi Tech   (Sweden)

Author keywords

Antiviral drug resistance; Cross resistance; Etravirine; HIV 1 reverse transcriptase; Low income countries; NNRTI

Indexed keywords

ACICLOVIR; ETRAVIRINE;

ANTIVIRAL SUSCEPTIBILITY; ARTICLE; COHORT ANALYSIS; CROSS RESISTANCE; DRUG RESISTANCE; GENE SEQUENCE; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHENOTYPE;

ANTI-HIV AGENTS; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PYRIDAZINES; SEQUENCE ANALYSIS, DNA;

EID: 84873972191     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23507     Document Type: Article

References (26)

1. Andries K, Azijn H, Thielemans T, Ludovici D, Kukla M, Heeres J, Janssen P, De Corte B, Vingerhoets J, Pauwels R, de Bethune MP. 2004. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 48:4680-4686.
2. Bacheler L, Jeffrey S, Hanna G, D'Aquila R, Wallace L, Logue K, Cordova B, Hertogs K, Larder B, Buckery R, Baker D, Gallagher K, Scarnati H, Tritch R, Rizzo C. 2001. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol 75:4999-5008.
3. Basson AE, Ntsala M, Martinson N, Tlale E, Corrigan GE, Shao X, Gray G, McIntyre J, Puren A, Morris L. 2008. Development of phenotypic HIV-1 drug resistance after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr 49:538-543.
4. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, Mannheimer SB, Thompson MA, Abrams DI, Brizz BJ, Ioannidis JP, Merigan TC. 2000. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 14:F83-F93.
5. Casado JL, Hertogs K, Ruiz L, Dronda F, Van Cauwenberge A, Arno A, Garcia-Arata I, Bloor S, Bonjoch A, Blazquez J, Clotet B, Larder B. 2000. Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen. AIDS 14:F1-F7.
6. Chetchotisakd P, Anunnatsiri S, Kiertiburanakul S, Sutthent R, Anekthananon T, Bowonwatanuwong C, Kowadisaiburana B, Supparatpinyo K, Horsakulthai M, Chasombat S, Ruxrungtham K. 2006. High rate multiple drug resistances in HIV-infected patients failing nonnucleoside reverse transcriptase inhibitor regimens in Thailand, where subtype A/E is predominant. J Int Assoc Physicians AIDS Care (Chic) 5:152-156.
7. Chou TC, Talalay P. 1984. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55.
8. De Corte BL. 2005. From 4, 5, 6, 7-tetrahydro-5-methylimidazo[4, 5, 1-jk](1, 4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): Fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase. J Med Chem 48:1689-1696.
9. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, Montagne N, Boucher CA, Schapiro JM, Dellamonica P. 1999. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial. Lancet 353:2195-2199.
10. Ekstrand DH, Awad RJ, Kallander CF, Gronowitz JS. 1996. A sensitive assay for the quantification of reverse transcriptase activity based on the use of carrier-bound template and non-radioactive-product detection, with special reference to human-immunodeficiency-virus isolation. Biotechnol Appl Biochem 23:95-105.
11. Hosseinipour MC, van Oosterhout JJ, Weigel R, Phiri S, Kamwendo D, Parkin N, Fiscus SA, Nelson JA, Eron JJ, Kumwenda J. 2009. The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 23:1127-1134.
12. Lennerstrand J, Hertogs K, Stammers DK, Larder BA. 2001. Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants. J Virol 75:7202-7205.
13. Lennerstrand J, Stammers DK, Larder BA. 2001. Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine. Antimicrob Agents Chemother 45:2144-2146.
14. Lindberg J, Sigurdsson S, Lowgren S, Andersson HO, Sahlberg C, Noreen R, Fridborg K, Zhang H, Unge T. 2002. Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant. Eur J Biochem 269:1670-1677.
15. Malmsten A, Shao XW, Aperia K, Corrigan GE, Sandstrom E, Kallander CF, Leitner T, Gronowitz JS. 2003. HIV-1 viral load determination based on reverse transcriptase activity recovered from human plasma. J Med Virol 71:347-359.
16. Malmsten A, Shao XW, Sjodahl S, Fredriksson EL, Pettersson I, Leitner T, Kallander CF, Sandstrom E, Gronowitz JS. 2005. Improved HIV-1 viral load determination based on reverse transcriptase activity recovered from human plasma. J Med Virol 76:291-296.
17. Picchio G, Vingerhoets J, Tambuyzer L, Coakley E, Haddad M, Witek J. 2011. Short communication prevalence of susceptibility to etravirine by genotype and phenotype in samples received for routine HIV type 1 resistance testing in the United States. AIDS Res Hum Retroviruses 27:1271-1275.
18. Shao XW, Hjalmarsson S, Lennerstrand J, Svennerholm B, Blomberg J, Kallander CF, Gronowitz JS. 2002. Application of a colorimetric chain-termination assay for characterization of reverse transcriptase from 3′-azido-2′, 3′-deoxythymidine-resistant HIV isolates. Biotechnol Appl Biochem 35:155-164.
19. Shao XW, Malmsten A, Lennerstrand J, Sonnerborg A, Unge T, Gronowitz JS, Kallander CF. 2003. Use of HIV-1 reverse transcriptase recovered from human plasma for phenotypic drug susceptibility testing. AIDS 17:1463-1471.
20. Stammers DK, Somers DO, Ross CK, Kirby I, Ray PH, Wilson JE, Norman M, Ren JS, Esnouf RM, Garman EF, Jones EY, Stuart DI. 1994. Crystals of HIV-1 reverse transcriptase diffracting to 2.2 A resolution. J Mol Biol 242:586-588.
21. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. 2007. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 44:447-452.
22. Tambuyzer L, Vingerhoets J, Azijn H, Daems B, Nijs S, de Bethune MP, Picchio G. 2010. Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies. AIDS Res Hum Retroviruses 26:1197-1205.
23. Tuaillon E, Gueudin M, Lemee V, Gueit I, Roques P, Corrigan GE, Plantier JC, Simon F, Braun J. 2004. Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups. J Acquir Immune Defic Syndr 37:1543-1549.
24. Vingerhoets J, Azijn H, Fransen E, De Baere I, Smeulders L, Jochmans D, Andries K, Pauwels R, de Bethune MP. 2005. TMC125 displays a high genetic barrier to the development of resistance: Evidence from in vitro selection experiments. J Virol 79:12773-12782.
25. Vingerhoets J, Tambuyzer L, Azijn H, Hoogstoel A, Nijs S, Peeters M, de Bethune MP, De Smedt G, Woodfall B, Picchio G. 2010. Resistance profile of etravirine: Combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS 24:503-514.
26. Weber JM, Sircar S, Horvath J, Dion P. 1989. Non-P-glycoprotein-mediated multidrug resistance in detransformed rat cells selected for resistance to methylglyoxal bis(guanylhydrazone). Cancer Res 49:5779-5783.